



## INFORMED CONSENT

### **Title of the case report:**

Topiramate induced peripheral neuropathy: a case report and review of literature

### **Corresponding author:**

Sherifa Ahmed Hamed (M.D.)

Consultant Neurologist

Professor

Department of Neurology and Psychiatry, Floor # 7, Room # 4, Hospital of Neurology and Psychiatry,

Assiut University Hospital

Assiut, Egypt

P.O.Box 71516

Telephone: +2 088 2371820

Cell phone: +2 01115324560

Fax : +2 088 2333327

+2 088 2332278

email: [hamed\\_sherifa@yahoo.com](mailto:hamed_sherifa@yahoo.com)

### **The purpose and introduction of the case report:**

We describe clinical and diagnostic features of a patient with peripheral neuropathy as an adverse effect of chronic topiramate (TPM) therapy.

**Case presentation:** A 37-year-old woman was presented for the control of active epilepsy which started since 7 years (2010). She was resistant to some AEDs as mono- or combined therapies (carbamazepine, sodium valproate, levetiracetam, oxcarbazepine and lamotrigine). She had the diagnosis of frontal lobe epilepsy with secondary generalization and had a brother, sister and a son with active epilepsy. She became seizure free on TPM since 3 years (2013-2017) but complained of distal lower-extremity paresthesia in a stocking distribution. She had diminished Achilles tendon reflexes, stocking hypesthesia of the lower extremities and delayed distal latencies and reduced motor and sensory conduction velocities of posterior tibial and sural nerves and reduced amplitudes of sensory action potential of both sural nerves, indicating demyelinating and axonal peripheral neuropathy of the lower extremities. After exclusion of the possible causes of peripheral neuropathy, we suggest that chronic TPM therapy is the cause of patient's neuropathy.

### **Corresponding author consent:**

I certify that I have given a translated document (Arabic copy) from the above consent form for the patient to sign after I ensured that confidentiality is maintained by not citing the patient's name in the paper or showing her name on any of the investigations and neurophysiology.

**Signature:** 

**Date:** 12/12/2015

**By signing below, I agree that I have read and understand the above information and agree for publishing my clinical, laboratory and imaging information.**

### **Printed name of the patient:**

Marwa Ahmed Hashim

مرؤة أحمد هاشم

**Signature:**

**Date:** 12/12/2015